metaEvidence - overview


			deaths (OS)
mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive
versus docetaxel
	atezolizumab alone vs. docetaxel	1	0.77 [0.64; 0.92], 1 RCT, I2=0% conclusive unassessable degree of certainty
	avelumab alone vs. docetaxel	1	0.90 [0.72; 1.12], 1 RCT, I2=0% inconclusive result
	pembrolizumab (10mg/kg) vs. docetaxel	2	0.58 [0.48; 0.69], 2 RCTs, I2=0% conclusive low degree of certainty
	pembrolizumab (2mg/kg) vs. docetaxel	2	0.64 [0.50; 0.83], 2 RCTs, I2=42% conclusive low degree of certainty
versus Standard of Care (SoC)
	durvalumab alone vs. Standard of Care (SoC)	1	0.63 [0.42; 0.94], 1 RCT, I2=0% unassessable degree of certainty